Evidence map›Paper›PMID 28507322›Full record

ArticleScientific reports2017

Rapid susceptibility profiling of carbapenem-resistant Klebsiella pneumoniae.

K T Mulroney, J M Hall, X Huang, E Turnbull, N M Bzdyl, A Chakera, U Naseer, E M Corea, M J Ellington, K L Hopkins and 4 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

K T MulroneyHarry Perkins Institute of Medical Research, School of Medicine, Faculty of Health and Medical Sciences, the University of Western Australia, Nedlands, Western Australia, Australia.
J M HallMarshall Centre, School of Biomedical Sciences, Faculty of Health and Medical Sciences, the University of Western Australia, Nedlands, Western Australia, Australia.
X HuangMarshall Centre, School of Biomedical Sciences, Faculty of Health and Medical Sciences, the University of Western Australia, Nedlands, Western Australia, Australia.
E TurnbullMarshall Centre, School of Biomedical Sciences, Faculty of Health and Medical Sciences, the University of Western Australia, Nedlands, Western Australia, Australia.
N M BzdylMarshall Centre, School of Biomedical Sciences, Faculty of Health and Medical Sciences, the University of Western Australia, Nedlands, Western Australia, Australia.
A ChakeraHarry Perkins Institute of Medical Research, School of Medicine, Faculty of Health and Medical Sciences, the University of Western Australia, Nedlands, Western Australia, Australia.
U NaseerNorwegian Institute of Public Health, Oslo, Norway.
E M CoreaDepartment of Microbiology, University of Colombo, Kynsey Road, Colombo, Sri Lanka.
M J EllingtonAntimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, London, NW9 5EQ, UK.
K L HopkinsAntimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, London, NW9 5EQ, UK.
A L WesterNorwegian Institute of Public Health, Oslo, Norway.
O EkelundDepartment of Clinical Microbiology and EUCAST Development Laboratory, Region Kronoberg, Växjö, Sweden.
N WoodfordAntimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, London, NW9 5EQ, UK.
T J J InglisMarshall Centre, School of Biomedical Sciences, Faculty of Health and Medical Sciences, the University of Western Australia, Nedlands, Western Australia, Australia. tim.inglis@health.wa.gov.au.ORCID 0000-0002-8559-8245

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expanding global distribution of multi-resistant Klebsiella pneumoniae demands faster antimicrobial susceptibility testing (AST) to guide antibiotic treatment. Current ASTs rely on time-consuming differentiation of resistance and susceptibility after initial isolation of bacteria from a clinical specimen. Here we describe a flow cytometry workflow to determine carbapenem susceptibility from bacterial cell characteristics in an international K. pneumoniae isolate collection (n = 48), with a range of carbapenemases. Our flow cytometry-assisted susceptibility test (FAST) method combines rapid qualitative susceptible/non-susceptible classification and quantitative MIC measurement in a single process completed shortly after receipt of a primary isolate (54 and 158 minutes respectively). The qualitative FAST results and FAST-derived MIC (MIC

Identifiers

PMID28507322
PMCPMC5432529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.